Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A de Graeff

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|February 20, 2015
Clinical relevance of the gap between pre-marketing trials and medical practice: the case of the cardiovascular drugsN F Wieringa, P Denig, P A de Graeff, et al.
Nederlands Tijdschrift Voor Geneeskunde|January 14, 2000
[Role of cytochrome P450 enzymes in pharmaceutical preparations]P A Baede van Dijk, P A de Graeff, J F Lekkerkerker
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 18, 2015
Risk attitudes and personality traits predict perceptions of benefits and risks for medicinal products: a field study of European medical assessorsAndrea R Beyer, Barbara Fasolo, P A de Graeff, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|May 20, 2004
Physicians' views on joint treatment guidelines for primary and secondary careW N Kasje, P Denig, P A De Graeff, et al.
Nederlands Tijdschrift Voor Geneeskunde|January 14, 1984
[Cholesterol emboli]B van Hoek, P A de Graeff, H G Kreeftenberg, et al.
Drugs & Aging|August 1, 1995
Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?J Brügemann, P A de Graeff, J van der Meer, et al.
International Journal of Cardiology|December 1, 1992
Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failureD J van Veldhuisen, A R Girbes, P A de Graeff, et al.
Cardiovascular Drugs and Therapy|July 1, 1997
Alterations in the prognosis of chronic heart failure: an overview of the major mortality trialsB M Szabó, D J van Veldhuisen, P A de Graeff, et al.
Journal of the American College of Cardiology|October 1, 1996
Value of digoxin in heart failure and sinus rhythm: new features of an old drug?D J van Veldhuisen, P A de Graeff, W J Remme, et al.
European Journal of Clinical Pharmacology|September 29, 1999
Cardiovascular drugs: discrepancies in demographics between pre- and post-registration useN F Wieringa, P A de Graeff, G T van der Werf, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|February 20, 2015
Clinical relevance of the gap between pre-marketing trials and medical practice: the case of the cardiovascular drugsN F Wieringa, P Denig, P A de Graeff, et al.
Nederlands Tijdschrift Voor Geneeskunde|January 14, 2000
[Role of cytochrome P450 enzymes in pharmaceutical preparations]P A Baede van Dijk, P A de Graeff, J F Lekkerkerker
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 18, 2015
Risk attitudes and personality traits predict perceptions of benefits and risks for medicinal products: a field study of European medical assessorsAndrea R Beyer, Barbara Fasolo, P A de Graeff, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|May 20, 2004
Physicians' views on joint treatment guidelines for primary and secondary careW N Kasje, P Denig, P A De Graeff, et al.
Nederlands Tijdschrift Voor Geneeskunde|January 14, 1984
[Cholesterol emboli]B van Hoek, P A de Graeff, H G Kreeftenberg, et al.
Drugs & Aging|August 1, 1995
Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?J Brügemann, P A de Graeff, J van der Meer, et al.
International Journal of Cardiology|December 1, 1992
Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failureD J van Veldhuisen, A R Girbes, P A de Graeff, et al.
Cardiovascular Drugs and Therapy|July 1, 1997
Alterations in the prognosis of chronic heart failure: an overview of the major mortality trialsB M Szabó, D J van Veldhuisen, P A de Graeff, et al.
Journal of the American College of Cardiology|October 1, 1996
Value of digoxin in heart failure and sinus rhythm: new features of an old drug?D J van Veldhuisen, P A de Graeff, W J Remme, et al.
European Journal of Clinical Pharmacology|September 29, 1999
Cardiovascular drugs: discrepancies in demographics between pre- and post-registration useN F Wieringa, P A de Graeff, G T van der Werf, et al.
Pageof 9